CSPC Pharmaceutical Group Co., Ltd. was established in August 1997. It has total assets of 15 billion yuan and more than 20,000 employees. It is the first large-scale pharmaceutical company in the national pharmaceutical industry to be established through a strong alliance. , is also one of the large pillar enterprise groups in Hebei Province.

CSPC Pharmaceutical Group has six major business sectors, and more than 30 companies including Zhongrun Pharmaceutical, Weisheng Pharmaceutical, Zhongnuo Pharmaceutical, Ouyi Pharmaceutical, Enbipu Pharmaceutical, Yinhu Pharmaceutical, etc. Subsidiary companies are located in Hebei, Tianjin, Jilin, Shanxi, Liaoning, Shandong, Inner Mongolia and Hong Kong. Among them, China Pharmaceutical Group Co., Ltd., a holding subsidiary in Hong Kong, is the first overseas listed company in the Chinese pharmaceutical industry and is currently the One of the largest pharmaceutical listed companies in Hong Kong and one of the constituent stocks of the Hong Kong Hang Seng Red Chip Index. It has been rated twice consecutively as one of the 100 outstanding listed companies in Asia with a turnover of less than US$1 billion by the world-famous "Forbes" magazine. .

CSPC Pharmaceutical Group is mainly engaged in the development, production and sales of pharmaceutical products. The products mainly include nearly a thousand varieties in seven series including antibiotics, vitamins, cardiovascular and cerebrovascular, antipyretic and analgesic, digestive system drugs, respiratory system drugs and Chinese patent medicines. Currently, the annual production capacity of eight products including vitamin C, penicillin, amoxicillin, caffeine, and 7-ACA ranks first in the world. CSPC Pharmaceutical Group's annual production capacity of pharmaceutical products is 3 billion injection powders, 20 billion tablets, 8 billion capsules, and 1 billion soft capsules. The output, scale and strength of CSPC's leading products are among the best in the country, and it has developed into one of the largest "chemical raw material pharmaceutical production bases" and "comprehensive preparation production bases" in China. At present, CSPC Pharmaceutical Group has 30 product varieties with sales exceeding 100 million yuan, and its products are sold throughout the country and more than 60 countries and regions around the world.

Since its establishment more than ten years ago, CSPC Pharmaceutical Group has continued to innovate and forge ahead with strong support from all walks of life, achieving sustained, healthy and rapid development and achieving gratifying results. The comprehensive strength of the enterprise has always been It is at the forefront of China's pharmaceutical industry and has won honorary titles such as the National Advanced Collective in the Pharmaceutical System, the Advanced Quality-Efficiency Enterprise, the Product Quality Assurance Commitment Unit, the National May Day Labor Certificate, and the China Environmental Protection Enterprise Love Award. In 2010, the group's sales revenue reached 13.088 billion yuan, a year-on-year increase of 23%, ranking second among national pharmaceutical industry enterprises for three consecutive years; profits and taxes were 1.605 billion yuan, a year-on-year increase of 1.022%; various taxes were paid 730 million yuan; and foreign exchange earnings from exports reached 5.5%. billion US dollars, a year-on-year increase of 22. Total exports continue to rank first in the domestic pharmaceutical industry.

In terms of scientific research and development, CSPC Pharmaceutical Group relies on the company's "Postdoctoral Research Workstation", national enterprise technology center, "863 Plan" high-tech industrialization base and Hebei Provincial Preparation Engineering Technology Center. In recent years, It has developed new drugs in more than 110 countries, involving biotechnology, chiral synthetic drugs, liposomes, transdermal preparations, molecular microcapsules and other fields. At present, CSPC Pharmaceutical Group has applied for more than 220 patents, of which 116 have been authorized. It has applied for 17 PCT international patents and has been authorized in 18 countries. Among them, "Enbipu", a national first-class new drug with independent intellectual property rights, is the world's leading drug in the field of stroke treatment. It is the third national first-class new drug with independent intellectual property rights in my country and is protected by patents in 86 countries around the world. . At present, the company has signed a patent transfer agreement for NBIPU soft capsules in the European, American and Korean markets with two well-known companies in the United States and South Korea, setting a precedent for Chinese pharmaceutical companies to transfer pharmaceutical intellectual property rights to the most developed countries in the world. The country and the nation have won honors. In 2008, under the leadership of the Ministry of Science and Technology, we took the lead in organizing and establishing the China Antibiotic Industry Technology Innovation Alliance, and received project support from the National Science and Technology Support Plan. In the national major science and technology application for “Major New Drug Creation”, one innovative drug incubation base, three innovative drug research and development technology platforms and six new drug development projects were settled in CSPC.

In 2009, the Group’s Pharmaceutical Preparation and Drug Release Technology Laboratory ranked among the “National Key Laboratories”, and the “Butylphthalide Raw Materials and Soft Capsules” project won the second prize of the National Science and Technology Progress Award. The Group was awarded the National Science and Technology Award, the State-owned Assets Supervision and Administration Commission of the State Council, the China The three ministries and commissions of the All-China Federation of Trade Unions jointly rated it as a "National Innovative Enterprise", marking that the group's innovation system has entered a new stage of systematization and institutionalization.

In terms of product quality, CSPC Pharmaceutical Group has established a complete three-level quality management system. All drugs have passed GMP certification. All subsidiaries have passed ISO9000, OHSAS18000 and ISO14001 certification, and the products have passed the market inspection. The rate always remains 100. At the same time, the company uses technology to improve quality connotation. Currently, 11 API products including caffeine, vitamin C, vitamin B12, and amoxicillin have obtained EU COS certification. In May 2010, the group's oral solid preparation workshop, vitamin C, and vitamin C sodium passed the U.S. FDA certification with the highest global drug quality standards with "zero defects". It is the first domestic preparation manufacturer to use domestic equipment to pass FDA certification. The first company in Asia to pass FDA certification for online production has obtained a "passport" to enter the high-end pharmaceutical market in Europe and the United States.

In terms of brand building, CSPC Pharmaceutical Group owns four "China Famous Trademarks": "CSPC", "Ouyi", "Guoweikang", "Enbipu"; According to one of the world's most valuable brand laboratory evaluations, the "CSPC Pharmaceuticals" brand has been selected into the "China's 500 Most Valuable Brands" for four consecutive times since 2005; CSPC Pharmaceutical Group has been among the top 500 Chinese companies for three consecutive times, and was shortlisted for the 2009 China's Most Valuable Brands Enterprise Award.

CSPC Pharmaceutical Group has always taken the lead in fulfilling its social responsibilities and has always enthusiastically supported social welfare undertakings. CSPC continues to contribute to the society through practical activities such as services and condolences to old communities. Since its establishment, CSPC has invested more than 60 million yuan in public welfare undertakings.